- Review
 
Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review
- Jonathan Shaw,
 - Ethan Kim,
 - Emily Ton,
 - Charles Lai,
 - Peter Bota and
 - Tina Allee
 
Aripiprazole is a third-generation antipsychotic, approved in 2002, notable for its partial agonism of the Dopamine D2 receptor and lower risk of metabolic and extrapyramidal adverse effects. It is available in a long-acting injectable formulation, w...

